Albany Molecular Res (AMRI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2004 | 09-2004 | 06-2004 | 03-2004 | 12-2003 | |
| Sales | 46,105 | 40,620 | 41,996 | 40,806 | 52,028 |
| Cost of Goods | 17,389 | 24,468 | 30,214 | 24,861 | 20,677 |
| Gross Profit | 28,716 | 16,152 | 11,782 | 15,945 | 31,351 |
| Operating Expenses | 23,774 | 12,323 | 34,582 | 12,662 | 16,565 |
| Operating Income | 5,331 | 4,297 | -22,586 | 4,144 | 15,463 |
| Interest Expense | 0 | 0 | 0 | 0 | 976 |
| Other Income | -1,264 | -23 | 143 | 104 | 1,058 |
| Pre-tax Income | 4,067 | 4,274 | -22,443 | 4,248 | 15,545 |
| Income Tax | 636 | 1,384 | -1,670 | 1,487 | 5,315 |
| Net Income Continuous | 3,431 | 2,890 | -20,773 | 2,761 | 10,230 |
| Net Income | $3,431 | $2,890 | $-20,773 | $2,761 | $10,230 |
| EPS Basic Total Ops | 0.10 | 0.09 | -0.65 | 0.09 | 0.32 |
| EPS Basic Continuous Ops | 0.11 | 0.09 | -0.65 | 0.09 | 0.32 |
| EPS Diluted Total Ops | 0.10 | 0.09 | -0.65 | 0.09 | 0.31 |
| EPS Diluted Continuous Ops | 0.11 | 0.09 | -0.65 | 0.09 | 0.32 |
| EBITDA(a) | $9,612 | $8,520 | $-4,420 | $7,678 | $19,074 |